Title
Evaluation of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients
Parallel Study, Double-blind, Randomized, to Compare the Safety of Two Therapies for the Treatment of Osteoarticular Inflammation in Dyspeptic Patients.
Phase
Phase 3Lead Sponsor
EMS S/AStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Acute and Chronic Inflammation DyspepsiaIntervention/Treatment
naproxen nimesulide pantoprazole esomeprazole ...Study Participants
490The purpose of this study is to evaluate the safety of an association with one anti-inflammatory and one gastroprotective agent compared to the one anti-inflammatory and one gastroprotective agent in patients with acute or chronic osteoarticular inflammation.
Double-blind,randomized, multicenter
Experiment duration: 14 days
03 visits
Evaluate the safety of an association with one anti-inflammatory and one gastroprotective compared to association with one anti-inflammatory and one gastroprotective agent in patients with acute or chronic osteoarticular inflammation
Adverse events evaluation
1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
Nimesulide + Pantoprazole- 1 tablet each 12 hours for 14 days
Naproxen + Esomeprazole - 1 tablet each 12 hours for 14 days
Inclusion Criteria: Adults male or female aged ≥ 18 years old; Comply with all the purposes and procedures of the study by signing and dating the Informed Consent. Acute or chronic osteo-articular injury in need of of anti-inflammatory for a period of 14 days. Exclusion Criteria: Pregnant women, or women in childbearing age who are not in use effective contraception or intending to become pregnant during the study period History of peptic ulcer or gastric surgery; Use of Non-steroidal anti-inflammatory (NSAIDs), aspirin, proton pump inhibitor (PPIs), H2 blocker and antacid in the past 7 days; Contraindication to the use of NSAIDs or PPIs; Renal or hepatic impairment;